Literature DB >> 18173443

Hepatitis C: a clinical review.

A A Modi1, T J Liang.   

Abstract

Hepatitis C is a major cause of chronic liver disease. It has been recognized as a global health problem because of the progression to cirrhosis and hepatocellular cancer. Chronic hepatitis C is usually asymptomatic but can cause considerable liver damage before its recognition. This review discusses the natural history, clinical features, diagnosis, therapy, treatment responses and the side effects associated with the treatment of hepatitis C.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18173443      PMCID： PMC2803488          DOI： 10.1111/j.1601-0825.2007.01419.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN： 1354-523X            Impact factor:   3.511


  33 in total

Review 1.  Natural history of hepatitis C: its impact on clinical management.

Authors:  A M Di Bisceglie
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

Review 2.  Peginterferon and ribavirin for chronic hepatitis C.

Authors:  Jay H Hoofnagle; Leonard B Seeff
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

Review 3.  American Gastroenterological Association technical review on the management of hepatitis C.

Authors:  Jules L Dienstag; John G McHutchison
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

4.  Treatment of hepatitis C: don't put all your eggs in one basket!

Authors:  Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2007-04       Impact factor: 22.682

Review 5.  Pathogenesis, natural history, treatment, and prevention of hepatitis C.

Authors:  T J Liang; B Rehermann; L B Seeff; J H Hoofnagle
Journal:  Ann Intern Med       Date:  2000-02-15       Impact factor: 25.391

Review 6.  Epidemiology of hepatitis C: geographic differences and temporal trends.

Authors:  A Wasley; M J Alter
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

7.  Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.

Authors:  Johannes Wiegand; Peter Buggisch; Wulf Boecher; Stefan Zeuzem; Cornelia M Gelbmann; Thomas Berg; Wolfgang Kauffmann; Birgit Kallinowski; Markus Cornberg; Elmar Jaeckel; Heiner Wedemeyer; Michael P Manns
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

8.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 9.  The economics of hepatitis C virus.

Authors:  Bhavesh B Shah; John B Wong
Journal:  Clin Liver Dis       Date:  2006-11       Impact factor: 6.126

10.  Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.

Authors:  Sanaa M Kamal; Amr E Fouly; Refaat R Kamel; Bridgette Hockenjos; Ahmed Al Tawil; Khalifa E Khalifa; Qi He; Margaret J Koziel; Khairy M El Naggar; Jens Rasenack; Nezam H Afdhal
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682
View more
  25 in total

Review 1.  Assessing gene-gene interactions in pharmacogenomics.

Authors:  Hsien-Yuan Lane; Guochuan E Tsai; Eugene Lin
Journal:  Mol Diagn Ther       Date:  2012-02-01       Impact factor: 4.074

2.  Exploring the Drug Resistance of HCV Protease.

Authors:  Garima Jindal; Dibyendu Mondal; Arieh Warshel
Journal:  J Phys Chem B       Date:  2017-07-05       Impact factor: 2.991

3.  Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.

Authors:  Ann D Kwong; Robert S Kauffman; Patricia Hurter; Peter Mueller
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

4.  Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument.

Authors:  Roger T Anderson; Robert W Baran; Birgitta Dietz; Eric Kallwitz; Pennifer Erickson; Dennis A Revicki
Journal:  Qual Life Res       Date:  2013-09-05       Impact factor: 4.147

5.  Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172.

Authors:  Djadé I Soumana; Nese Kurt Yilmaz; Kristina L Prachanronarong; Cihan Aydin; Akbar Ali; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2016-01-06       Impact factor: 5.100

6.  Increased Spontaneous Programmed Cell Death Is Associated with Impaired Cytokine Secretion in Peripheral Blood Mononuclear Cells from Hepatitis C Virus-Positive Patients.

Authors:  Abdulkarim Alhetheel; Ahmed Albarrag; Zahid Shakoor; Khalid Alswat; Ayman Abdo; Waleed Al-Hamoudi; Suliman Alomar
Journal:  Viral Immunol       Date:  2017-03-17       Impact factor: 2.257

Review 7.  Improving Viral Protease Inhibitors to Counter Drug Resistance.

Authors:  Nese Kurt Yilmaz; Ronald Swanstrom; Celia A Schiffer
Journal:  Trends Microbiol       Date:  2016-04-15       Impact factor: 17.079

Review 8.  Review of patient-reported outcome measures in chronic hepatitis C.

Authors:  Leah Kleinman; Sally Mannix; Yong Yuan; Shannon Kummer; Gilbert L'Italien; Dennis Revicki
Journal:  Health Qual Life Outcomes       Date:  2012-08-07       Impact factor: 3.186

9.  Pharmacogenomics of drug efficacy in the interferon treatment of chronic hepatitis C using classification algorithms.

Authors:  Wan-Sheng Ke; Yuchi Hwang; Eugene Lin
Journal:  Adv Appl Bioinform Chem       Date:  2010-06-15

10.  Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations.

Authors:  Paul G Carty; Christopher G Fawsitt; Paddy Gillespie; Patricia Harrington; Michelle O'Neill; Susan M Smith; Conor Teljeur; Mairin Ryan
Journal:  Appl Health Econ Health Policy       Date:  2021-12-06       Impact factor: 3.686
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.